Bodhi Tree Biotechnology Inc (BDTB)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-14

Key Insights

  • Company is severely cash-constrained with only $22,750 in cash as of March 31, 2026, down 79% from $109,404 six months prior, raising immediate liquidity concerns for ongoing operations.
  • Accumulated deficit has grown to $293,763 with net losses of $82,144 for the six-month period, while revenue remains minimal at $15,000, indicating the company is not generating meaningful business traction.
  • General and administrative expenses of $95,883 for six months significantly exceed the company's revenue, demonstrating an unsustainable burn rate with no clear path to profitability or operational viability.
  • The company is a non-accelerated filer, smaller reporting company, and emerging growth company trading OTC, suggesting limited resources, visibility, and market capitalization to support business development.
Quarterly Report Filed: 2026-02-13

Key Insights

  • Bodhi Tree Biotechnology Inc. reported a net loss of $52,948 for the quarter ended December 31, 2025, an improvement from the $64,777 loss in the same period of the prior year.
  • The company's cash balance declined to $47,366 as of December 31, 2025, down from $109,404 at the end of the prior quarter, indicating potential liquidity concerns.
  • Bodhi Tree Biotechnology did not generate any revenue during the quarter, a decline from the $5,000 in revenue reported in the same period of the prior year, raising questions about the company's commercial progress.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.